Highlights

  • Imricor Medical Systems (ASX:IMR) reported 2QCY26 revenue of USD 60,500, down from USD 65,200 a year earlier.
  • Net operating cash outflow was USD 6.1mn in 2QCY26, compared with USD 7.9mn in 1QCY26.
  • The company commenced a U.S. commercial rollout of NorthStar with its first hospital customer.
  • The U.S. regulator completed review of the third premarket approval module in October 2026.

Imricor Medical Systems, Inc. develops magnetic resonance imaging-compatible equipment and devices for cardiac catheterisation and electrophysiology procedures, with NorthStar forming part of its interventional MR platform. On 26 October 2026, Imricor Medical Systems (ASX:IMR) was quoted at AUD 1.303, up 0.19% during the trading session. Its latest operating disclosures concern the U.S. commercial launch, regulatory submissions for MRI-guided ablation technology and funding for broader hospital adoption.

Company Business

Imricor Medical Systems (ASX:IMR) is based in Burnsville, Minnesota, and develops devices intended to support cardiac interventions performed under real-time magnetic resonance guidance. The approach gives clinicians MR imaging during procedures traditionally conducted using X-ray fluoroscopy. Its products comprise capital equipment, software and disposable medical devices designed for use in dedicated interventional MR laboratories.

The NorthStar mapping and guidance system and Advantage-MR electrophysiology recorder/stimulator are among the company’s capital products. Its Vision-MR range includes diagnostic and ablation catheters, while other components cover introducers and associated laboratory equipment. Commercial activities encompass the United States and European hospital markets, alongside regulatory and clinical programs.

Recent Development

During the second half of 2026, Imricor Medical Systems (ASX:IMR) advanced its U.S. hospital sales program. It identified Rady Children’s Hospital–San Diego as the first U.S. commercial customer for NorthStar, supporting the establishment of an MR-guided cardiac catheterisation service. The company also launched a cardiovascular business segment focused on catheterisation procedures and expanded its U.S. commercial staffing.

In August 2026, the company announced a commercial interventional MR laboratory solution in collaboration with Philips. Its previously disclosed compatibility assessment was intended to widen the types of MR installations able to host its technology. Whether additional hospitals complete procurement, installation and clinical activation remains central to commercial execution.

On 8 October 2026, Imricor Medical Systems (ASX:IMR) reported that the U.S. Food and Drug Administration had completed review of the third module of the premarket approval application covering the Vision-MR Ablation Catheter 2.0 and associated system. The process had not resulted in final marketing approval. Outstanding regulatory work includes completion of the application, any required responses and manufacturing-site inspection.

Financial Performance and Sector Context

The 2QCY26 quarterly activities report recorded revenue of USD 60,500, compared with USD 65,200 in 2QCY25, a decline of approximately 6% YoY. Management stated that clinical-trial use of consumable devices was not recognised as commercial sales revenue, affecting reported turnover. The quarterly net loss was USD 7.4mn, compared with USD 7.8mn in 2QCY25.

Net operating cash outflow amounted to USD 6.1mn in 2QCY26, versus USD 7.9mn in 1QCY26. Cash and short-term investments totalled USD 67.5mn at 30 June 2026. Following subsequent option exercises generating approximately USD 2.1mn, the company reported a pro forma funding position of USD 69.6mn at that date. A placement completed during the quarter raised AUD 60mn before associated costs.

Hospital adoption of MRI-guided interventions depends on equipment purchasing cycles, room configuration, clinical training, regulatory permissions and procedural evidence. Consequently, product clearances and initial sales do not immediately translate into recurring consumables demand across all hospital sites.

Risks to Consider

Imricor Medical Systems (ASX:IMR) remains exposed to regulatory review and clinical-trial risks, including timelines for completing its VISABL-AFL study and securing approval of the ablation system. Hospital purchasing decisions, installation schedules and staffing may delay revenue recognition. Continued operating losses and product development costs create funding requirements, while manufacturing readiness and the pace of consumable utilisation influence commercial performance.

What to Watch Next

The next developments for Imricor Medical Systems (ASX:IMR) include NorthStar installations at U.S. hospitals, any new commercial purchase agreements, the pace of VISABL-AFL recruitment and submission of the final premarket approval module. Further FDA correspondence, additional device clearances and quarterly cash-flow updates will clarify progress in regulatory and commercial operations.

Key Insights

Imricor’s 2026 updates show an expanding U.S. commercial presence alongside a multistage FDA review of its ablation technology. Revenue remains limited relative to expenditure, although the completed financing increased available funds. Hospital deployment, regulatory outcomes and subsequent cash consumption will provide measurable indications of execution.